Cargando…
Combining MOE Bioinformatics Analysis and In Vitro Pseudovirus Neutralization Assays to Predict the Neutralizing Ability of CV30 Monoclonal Antibody on SARS-CoV-2 Variants
Combining bioinformatics and in vitro cytology assays, a predictive method was established to quickly evaluate the protective effect of immunity acquired through SARS-CoV-2 infection against variants. Bioinformatics software was first used to predict the changes in the affinity of variant antigens t...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386485/ https://www.ncbi.nlm.nih.gov/pubmed/37515251 http://dx.doi.org/10.3390/v15071565 |
_version_ | 1785081676815138816 |
---|---|
author | Zhu, Yajuan Xiong, Husheng Liu, Shuang Wu, Dawei Zhang, Xiaomin Shi, Xiaolu Qu, Jing Chen, Long Liu, Zheng Peng, Bo Zhang, Dingmei |
author_facet | Zhu, Yajuan Xiong, Husheng Liu, Shuang Wu, Dawei Zhang, Xiaomin Shi, Xiaolu Qu, Jing Chen, Long Liu, Zheng Peng, Bo Zhang, Dingmei |
author_sort | Zhu, Yajuan |
collection | PubMed |
description | Combining bioinformatics and in vitro cytology assays, a predictive method was established to quickly evaluate the protective effect of immunity acquired through SARS-CoV-2 infection against variants. Bioinformatics software was first used to predict the changes in the affinity of variant antigens to the CV30 monoclonal antibody by integrating bioinformatics and cytology assays. Then, the ability of the antibody to neutralize the variant antigen was further verified, and the ability of the CV30 to neutralize the new variant strain was predicted through pseudovirus neutralization experiments. The current study has demonstrated that when the Molecular Operating Environment (MOE) predicts |ΔBFE| ≤ 3.0003, it suggests that the CV30 monoclonal antibody exhibits some affinity toward the variant strain and can potentially neutralize it. However, if |ΔBFE| ≥ 4.1539, the CV30 monoclonal antibody does not display any affinity for the variant strain and cannot neutralize it. In contrast, if 3.0003 < |ΔBFE| < 4.1539, it is necessary to conduct a series of neutralization tests promptly with the CV30 monoclonal antibody and the variant pseudovirus to obtain results and supplement the existing method, which is faster than the typical procedures. This approach allows for a rapid assessment of the protective efficacy of natural immunity gained through SARS-CoV-2 infection against variants. |
format | Online Article Text |
id | pubmed-10386485 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103864852023-07-30 Combining MOE Bioinformatics Analysis and In Vitro Pseudovirus Neutralization Assays to Predict the Neutralizing Ability of CV30 Monoclonal Antibody on SARS-CoV-2 Variants Zhu, Yajuan Xiong, Husheng Liu, Shuang Wu, Dawei Zhang, Xiaomin Shi, Xiaolu Qu, Jing Chen, Long Liu, Zheng Peng, Bo Zhang, Dingmei Viruses Article Combining bioinformatics and in vitro cytology assays, a predictive method was established to quickly evaluate the protective effect of immunity acquired through SARS-CoV-2 infection against variants. Bioinformatics software was first used to predict the changes in the affinity of variant antigens to the CV30 monoclonal antibody by integrating bioinformatics and cytology assays. Then, the ability of the antibody to neutralize the variant antigen was further verified, and the ability of the CV30 to neutralize the new variant strain was predicted through pseudovirus neutralization experiments. The current study has demonstrated that when the Molecular Operating Environment (MOE) predicts |ΔBFE| ≤ 3.0003, it suggests that the CV30 monoclonal antibody exhibits some affinity toward the variant strain and can potentially neutralize it. However, if |ΔBFE| ≥ 4.1539, the CV30 monoclonal antibody does not display any affinity for the variant strain and cannot neutralize it. In contrast, if 3.0003 < |ΔBFE| < 4.1539, it is necessary to conduct a series of neutralization tests promptly with the CV30 monoclonal antibody and the variant pseudovirus to obtain results and supplement the existing method, which is faster than the typical procedures. This approach allows for a rapid assessment of the protective efficacy of natural immunity gained through SARS-CoV-2 infection against variants. MDPI 2023-07-17 /pmc/articles/PMC10386485/ /pubmed/37515251 http://dx.doi.org/10.3390/v15071565 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zhu, Yajuan Xiong, Husheng Liu, Shuang Wu, Dawei Zhang, Xiaomin Shi, Xiaolu Qu, Jing Chen, Long Liu, Zheng Peng, Bo Zhang, Dingmei Combining MOE Bioinformatics Analysis and In Vitro Pseudovirus Neutralization Assays to Predict the Neutralizing Ability of CV30 Monoclonal Antibody on SARS-CoV-2 Variants |
title | Combining MOE Bioinformatics Analysis and In Vitro Pseudovirus Neutralization Assays to Predict the Neutralizing Ability of CV30 Monoclonal Antibody on SARS-CoV-2 Variants |
title_full | Combining MOE Bioinformatics Analysis and In Vitro Pseudovirus Neutralization Assays to Predict the Neutralizing Ability of CV30 Monoclonal Antibody on SARS-CoV-2 Variants |
title_fullStr | Combining MOE Bioinformatics Analysis and In Vitro Pseudovirus Neutralization Assays to Predict the Neutralizing Ability of CV30 Monoclonal Antibody on SARS-CoV-2 Variants |
title_full_unstemmed | Combining MOE Bioinformatics Analysis and In Vitro Pseudovirus Neutralization Assays to Predict the Neutralizing Ability of CV30 Monoclonal Antibody on SARS-CoV-2 Variants |
title_short | Combining MOE Bioinformatics Analysis and In Vitro Pseudovirus Neutralization Assays to Predict the Neutralizing Ability of CV30 Monoclonal Antibody on SARS-CoV-2 Variants |
title_sort | combining moe bioinformatics analysis and in vitro pseudovirus neutralization assays to predict the neutralizing ability of cv30 monoclonal antibody on sars-cov-2 variants |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386485/ https://www.ncbi.nlm.nih.gov/pubmed/37515251 http://dx.doi.org/10.3390/v15071565 |
work_keys_str_mv | AT zhuyajuan combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants AT xionghusheng combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants AT liushuang combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants AT wudawei combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants AT zhangxiaomin combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants AT shixiaolu combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants AT qujing combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants AT chenlong combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants AT liuzheng combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants AT pengbo combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants AT zhangdingmei combiningmoebioinformaticsanalysisandinvitropseudovirusneutralizationassaystopredicttheneutralizingabilityofcv30monoclonalantibodyonsarscov2variants |